Milton Essex Spólka Akcyjna (WSE:MTN) Full Year 2024 Results
Key Financial Results
- Revenue: zł621.7k (up 55% from FY 2023).
- Net income: zł150.2k (up from zł612.7k loss in FY 2023).
- Profit margin: 24% (up from net loss in FY 2023). The move to profitability was primarily driven by higher revenue.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Milton Essex Spólka Akcyjna shares are down 21% from a week ago.
Risk Analysis
You should always think about risks. Case in point, we've spotted 4 warning signs for Milton Essex Spólka Akcyjna you should be aware of.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About WSE:MTN
Milton Essex Spólka Akcyjna
Engages in the development and sale of medical devices.
Flawless balance sheet slight.
Market Insights
Community Narratives
